Phenotypical and Functional Characterization of the CD8+ T Cell Repertoire of HLA-A2.1 Transgenic, H-2KbnullDbnull Double Knockout Mice
Overview
Authors
Affiliations
Homozygous HLA-A2.1 transgenic H-2KbnullDbnull double knockout (KO) mice were created. Their potential to develop HLA-A2. 1-restricted cytolytic responses was compared with that of their classical transgenic counterparts, which still express H-2Kb, Db molecules. On cell surfaces, both strains express similar amounts of chimeric (alpha 1 alpha 2 domains of human, alpha 3 cytoplasmic domains of mouse) HLA-A2.1 molecules in noncovalent association with mouse beta 2-microglobulin. Compared with mice that are totally deprived of histocompatibility class Ia molecules (H-2KbnullDbnull double KO), the expression of HLA-A2.1 in transgenic/double KO mice resulted in sizeable increase in the periphery of CD8+ T cells with a normally diversified TCR repertoire. A biased education in favor of HLA-A2.1, ascribable to the absence of H-2 class Ia molecules, was evidenced in these transgenic/double KO mice by their improved capacity to mount HLA-restricted cytolytic responses, regardless of whether they were virally infected or injected with synthetic epitopic peptide. HLA class I transgenic, H-2 class Ia KO mice should represent useful animal models for the preclinical evaluation of vaccine formulations aiming at the induction of HLA class I-restricted CTL responses.
Kumar S, Nan L, Kalodimou G, Jany S, Freudenstein A, Brandmuller C Int J Mol Sci. 2024; 25(20).
PMID: 39456680 PMC: 11508112. DOI: 10.3390/ijms252010898.
Ananthula S, Krishnaveni Sivakumar K, Cardone M, Su S, Roderiquez G, Abuzeineh H J Allergy Clin Immunol. 2023; 152(2):486-499.e7.
PMID: 37030592 PMC: 10524621. DOI: 10.1016/j.jaci.2023.03.029.
Generation of human MHC (HLA-A11/DR1) transgenic mice for vaccine evaluation.
Zeng Y, Gao T, Zhao G, Jiang Y, Yang Y, Yu H Hum Vaccin Immunother. 2015; 12(3):829-36.
PMID: 26479036 PMC: 4964720. DOI: 10.1080/21645515.2015.1103405.
The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects.
Oliveira C, Van Veelen P, Querido B, de Ru A, Sluijter M, Laban S J Exp Med. 2009; 207(1):207-21.
PMID: 20038604 PMC: 2812552. DOI: 10.1084/jem.20091429.
Krishnan A, Wang Z, Srivastava T, Rawal R, Manchanda P, Diamond D Immunol Lett. 2008; 120(1-2):108-16.
PMID: 18706443 PMC: 2577668. DOI: 10.1016/j.imlet.2008.07.010.